These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 19940106

  • 1. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.
    Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T, Ohashi N, Nakano D, Hitomi H, Imanishi M.
    J Pharmacol Exp Ther; 2010 Mar; 332(3):1072-80. PubMed ID: 19940106
    [Abstract] [Full Text] [Related]

  • 2. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.
    Nishiyama A, Nakagawa T, Kobori H, Nagai Y, Okada N, Konishi Y, Morikawa T, Okumura M, Meda I, Kiyomoto H, Hosomi N, Mori T, Ito S, Imanishi M.
    J Hypertens; 2008 Sep; 26(9):1849-59. PubMed ID: 18698221
    [Abstract] [Full Text] [Related]

  • 3. Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.
    Liang W, Chen C, Shi J, Ren Z, Hu F, van Goor H, Singhal PC, Ding G.
    Nephrol Dial Transplant; 2011 Mar; 26(3):789-99. PubMed ID: 20729265
    [Abstract] [Full Text] [Related]

  • 4. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
    Sofue T, Kiyomoto H, Kobori H, Urushihara M, Nishijima Y, Kaifu K, Hara T, Matsumoto S, Ichimura A, Ohsaki H, Hitomi H, Kawachi H, Hayden MR, Whaley-Connell A, Sowers JR, Ito S, Kohno M, Nishiyama A.
    Am J Hypertens; 2012 May; 25(5):604-11. PubMed ID: 22318512
    [Abstract] [Full Text] [Related]

  • 5. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
    Fukuda A, Fujimoto S, Iwatsubo S, Kawachi H, Kitamura K.
    Nephrology (Carlton); 2010 Apr; 15(3):321-6. PubMed ID: 20470301
    [Abstract] [Full Text] [Related]

  • 6. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR.
    Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
    [Abstract] [Full Text] [Related]

  • 7. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ, Noma T, Kohno M, Nishiyama A, Nakano D.
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [Abstract] [Full Text] [Related]

  • 8. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, Nakhoul N, Hoffman A, Abassi Z.
    Am J Physiol Renal Physiol; 2008 Mar; 294(3):F628-37. PubMed ID: 18094029
    [Abstract] [Full Text] [Related]

  • 9. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
    Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T.
    Hypertension; 2007 Feb; 49(2):355-64. PubMed ID: 17200434
    [Abstract] [Full Text] [Related]

  • 10. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
    Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T.
    Hypertension; 2006 Jun; 47(6):1084-93. PubMed ID: 16636193
    [Abstract] [Full Text] [Related]

  • 11. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C, VIVALDI investigators.
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
    Bichu P, Nistala R, Khan A, Sowers JR, Whaley-Connell A.
    Vasc Health Risk Manag; 2009 Oct; 5(1):129-40. PubMed ID: 19436679
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with telmisartan and oxacalcitriol suppresses the progression of murine adriamycin nephropathy.
    Jeong KH, Asanuma K, Lydia A, Takagi M, Asao R, Kodama F, Asanuma E, Tomino Y.
    Nephron; 2015 Oct; 129(2):143-54. PubMed ID: 25661164
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
    Zhao ZQ, Luo R, Li LY, Tian FS, Zheng XL, Xiong HL, Sun LT.
    Can J Diabetes; 2013 Jun; 37(3):156-68. PubMed ID: 24070838
    [Abstract] [Full Text] [Related]

  • 15. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?
    Tylicki L, Lizakowski S, Rutkowski P, Renke M, Sulikowska B, Heleniak Z, Donderski R, Bednarski R, Przybylska M, Manitius J, Rutkowski B.
    Kidney Blood Press Res; 2012 Jun; 36(1):335-43. PubMed ID: 23235363
    [Abstract] [Full Text] [Related]

  • 16. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
    Nakhoul F, Ramadan R, Khankin E, Yaccob A, Kositch Z, Lewin M, Assady S, Abassi Z.
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F880-90. PubMed ID: 15942045
    [Abstract] [Full Text] [Related]

  • 17. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade.
    Ihara G, Kiyomoto H, Kobori H, Nagai Y, Ohashi N, Hitomi H, Nakano D, Pelisch N, Hara T, Mori T, Ito S, Kohno M, Nishiyama A.
    J Hypertens; 2010 Nov; 28(11):2289-98. PubMed ID: 20706133
    [Abstract] [Full Text] [Related]

  • 18. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.
    Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, Hirakawa M, Taniguchi M, Masutani K, Iida M.
    Nephrol Dial Transplant; 2011 Aug; 26(8):2475-84. PubMed ID: 21220752
    [Abstract] [Full Text] [Related]

  • 19. Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
    Villa L, Boor P, Konieczny A, Kunter U, van Roeyen CR, Denecke B, Gan L, Neusser MA, Cohen CD, ERCB Consortium;, Eitner F, Scholl T, Ostendorf T, Floege J.
    J Pathol; 2013 Apr; 229(5):672-84. PubMed ID: 23192593
    [Abstract] [Full Text] [Related]

  • 20. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
    Xu HZ, Wang WN, Zhang YY, Cheng YL, Xu ZG.
    J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.